These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Commentary: data monitoring confidentiality and FDA transparency. London AJ Clin Trials; 2015 Feb; 12(1):12-4. PubMed ID: 25525073 [No Abstract] [Full Text] [Related]
5. Protecting the confidentiality of interim data: addressing current challenges. Fleming TR Clin Trials; 2015 Feb; 12(1):5-11. PubMed ID: 25475877 [TBL] [Abstract][Full Text] [Related]
6. Maintaining confidentiality of interim data to enhance trial integrity and credibility. Fleming TR; Sharples K; McCall J; Moore A; Rodgers A; Stewart R Clin Trials; 2008; 5(2):157-67. PubMed ID: 18375654 [TBL] [Abstract][Full Text] [Related]
7. [Data monitoring committees. Third pillar in the methodical conduct of clinical trials]. Fischer T Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):793-6. PubMed ID: 18563280 [TBL] [Abstract][Full Text] [Related]
8. Striding forward or getting too big for their boots? The developing role of data monitoring committees in clinical trials. Tharmanathan P; Calvert MJ; Freemantle N J Clin Pharm Ther; 2006 Apr; 31(2):111-8. PubMed ID: 16635044 [No Abstract] [Full Text] [Related]
10. Monitoring data on data monitoring. Ellenberg SS Clin Trials; 2004 Feb; 1(1):6-8. PubMed ID: 16281457 [No Abstract] [Full Text] [Related]
11. Standard versus adaptive monitoring procedures: A commentary. Fleming TR Stat Med; 2006 Oct; 25(19):3305-12; discussion 3313-4, 3326-47. PubMed ID: 16850447 [TBL] [Abstract][Full Text] [Related]
12. Who's minding the data? Data Monitoring Committees in clinical cancer trials. Keating P; Cambrosio A Sociol Health Illn; 2009 Apr; 31(3):325-42. PubMed ID: 19055588 [TBL] [Abstract][Full Text] [Related]
13. A domain model of a clinical reading center - Design and implementation. Lotz G; Peters T; Zrenner E; Wilke R Annu Int Conf IEEE Eng Med Biol Soc; 2010; 2010():4530-3. PubMed ID: 21095788 [TBL] [Abstract][Full Text] [Related]
14. A major trial needs three statisticians: why, how and who? Pocock SJ Stat Med; 2004 May; 23(10):1535-9. PubMed ID: 15122734 [TBL] [Abstract][Full Text] [Related]
15. Data safety monitoring boards: a word from a sponsor (NHLBI). Mondoro TH Transfusion; 2009 Aug; 49(8):1537-9. PubMed ID: 19413736 [No Abstract] [Full Text] [Related]
16. The Absence of an Ideal Observer: Why Some Clinical Trials May Not Be What We Think They Are. Packer M Circulation; 2017 Sep; 136(12):1085-1086. PubMed ID: 28923903 [No Abstract] [Full Text] [Related]
17. Planning and core analyses for periodic aggregate safety data reviews. Xia HA; Crowe BJ; Schriver RC; Oster M; Hall DB Clin Trials; 2011 Apr; 8(2):175-82. PubMed ID: 21270142 [TBL] [Abstract][Full Text] [Related]
18. Role of the data safety and monitoring board in an international trial. NIMH Collaborative HIV/STD Prevention Trial AIDS; 2007 Apr; 21 Suppl 2():S99-102. PubMed ID: 17413269 [TBL] [Abstract][Full Text] [Related]
19. Research ethics review for the use of anonymized samples and data: A systematic review of normative documents. Phillips A; Borry P; Shabani M Account Res; 2017; 24(8):483-496. PubMed ID: 29140743 [TBL] [Abstract][Full Text] [Related]
20. Monitoring reportable events and unanticipated problems: the PHAROS and PREDICT studies of Huntington disease. Erwin C; Hersch S; IRB; 2007; 29(3):11-6. PubMed ID: 17847637 [No Abstract] [Full Text] [Related] [Next] [New Search]